TY - JOUR
T1 - Different structures of the two peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist
AU - Ohashi, Masao
AU - Oyama, Takuji
AU - Miyachi, Hiroyuki
N1 - Funding Information:
This work was supported in part by a grant for Platform for Drug Discovery, Informatics, and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology, Japan, Terumo Foundation and a Grant in-aid for Scientific Research (B) (grant number 26293027 to H.M.) from the Ministry of Education, Culture, Sports, Science and Technology ( MEXT ). We also thank the SC-NMR Laboratory of Okayama University for NMR measurements.
Publisher Copyright:
© 2015 Elsevier Ltd. All rights reserved.
PY - 2015/5/30
Y1 - 2015/5/30
N2 - We designed and synthesized acylsulfonamide derivative (3) as a human peroxisome proliferator-activated receptor gamma (hPPARγ) partial agonist by structural modification of hPPARγ full agonist 1. Co-crystallization of 3 with hPPARγ LBD afforded a homodimeric complex, and X-ray crystallographic analysis at 2.1 Å resolution showed that one of the LBDs adopts a fully active structure identical with that in the complex of rosiglitazone, a full agonist; however, the other LBD in the complex of 3 exhibits a different (non-fully active) structure. Interestingly, the apo-homodimer contained similar LBD structures. Intrigued by these results, we surveyed reported X-ray crystal structures of partial agonists complexed with hPPARγ LBD homodimer, and identified several types of LBD structures distinct from the fully active structure. In contrast, both LBDs in the rosiglitazone complex have the fully active structure. These results suggest hPPARγ partial agonists lack the ability to induce fully active LBD. The presence of at least one non-fully active LBD in the agonist complex may be a useful criterion to distinguish hPPARγ partial agonists from full agonists.
AB - We designed and synthesized acylsulfonamide derivative (3) as a human peroxisome proliferator-activated receptor gamma (hPPARγ) partial agonist by structural modification of hPPARγ full agonist 1. Co-crystallization of 3 with hPPARγ LBD afforded a homodimeric complex, and X-ray crystallographic analysis at 2.1 Å resolution showed that one of the LBDs adopts a fully active structure identical with that in the complex of rosiglitazone, a full agonist; however, the other LBD in the complex of 3 exhibits a different (non-fully active) structure. Interestingly, the apo-homodimer contained similar LBD structures. Intrigued by these results, we surveyed reported X-ray crystal structures of partial agonists complexed with hPPARγ LBD homodimer, and identified several types of LBD structures distinct from the fully active structure. In contrast, both LBDs in the rosiglitazone complex have the fully active structure. These results suggest hPPARγ partial agonists lack the ability to induce fully active LBD. The presence of at least one non-fully active LBD in the agonist complex may be a useful criterion to distinguish hPPARγ partial agonists from full agonists.
KW - Acylsulfonamide derivative
KW - Homodimeric complex
KW - PPAR
KW - X-ray crystallographic analysis
UR - http://www.scopus.com/inward/record.url?scp=84930082453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930082453&partnerID=8YFLogxK
U2 - 10.1016/j.bmcl.2015.04.076
DO - 10.1016/j.bmcl.2015.04.076
M3 - Article
AN - SCOPUS:84930082453
SN - 0960-894X
VL - 25
SP - 2639
EP - 2644
JO - Bioorganic and Medicinal Chemistry Letters
JF - Bioorganic and Medicinal Chemistry Letters
IS - 13
ER -